UBS Group’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-2,608
| Closed | -$29.7K | – | 10452 |
|
|
2023
Q4 | $29.7K | Buy |
2,608
+2,554
| +4,730% | +$20.1K | ﹤0.01% | 6854 |
|
|
2023
Q3 | $218 | Sell |
54
-260
| -83% | -$1.93K | ﹤0.01% | 8684 |
|
|
2023
Q2 | $2.23K | Buy |
314
+60
| +24% | +$415 | ﹤0.01% | 7786 |
|
|
2023
Q1 | $1.89K | Hold |
254
| – | – | ﹤0.01% | 8625 |
|
|
2022
Q4 | $1.86K | Buy |
254
+3
| +1% | +$25 | ﹤0.01% | 9780 |
|
|
2022
Q3 | $2K | Buy |
251
+187
| +292% | +$3.49K | ﹤0.01% | 9846 |
|
|
2022
Q2 | $1K | Sell |
64
-246
| -79% | -$6.37K | ﹤0.01% | 10098 |
|
|
2022
Q1 | $15K | Sell |
310
-476
| -61% | -$24.7K | ﹤0.01% | 7873 |
|
|
2021
Q4 | $59K | Buy |
786
+740
| +1,609% | +$50.5K | ﹤0.01% | 6758 |
|
|
2021
Q3 | $4K | Sell |
46
-641
| -93% | -$64.4K | ﹤0.01% | 8725 |
|
|
2021
Q2 | $96K | Buy |
687
+614
| +841% | +$117K | ﹤0.01% | 5915 |
|
|
2021
Q1 | $15K | Buy |
73
+71
| +3,550% | +$14.2K | ﹤0.01% | 7644 |
|
|
2020
Q4 | $0 | Sell |
2
-312
| -99% | -$48.2K | ﹤0.01% | 8918 |
|
|
2020
Q3 | $53K | Sell |
314
-366
| -54% | -$52.8K | ﹤0.01% | 5610 |
|
|
2020
Q2 | $113K | Sell |
680
-101
| -13% | -$15.8K | ﹤0.01% | 5211 |
|
|
2020
Q1 | $91K | Sell |
781
-565
| -42% | -$79.4K | ﹤0.01% | 5371 |
|
|
2019
Q4 | $199K | Buy |
1,346
+777
| +137% | +$118K | ﹤0.01% | 5610 |
|
|
2019
Q3 | $78K | Buy |
569
+463
| +437% | +$65.1K | ﹤0.01% | 5914 |
|
|
2019
Q2 | $14K | Buy |
+106
| New | +$12.3K | ﹤0.01% | 6864 |
|
UBS Group's HARP Position: Q1 2024 in Review
UBS Group sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2024, closing a stake of 2,608 shares — an estimated $29.7K sold.
UBS Group first reported a position in HARP in Q2 2019 and held it in 19 quarters. The position peaked at $199K in Q4 2019. 0 funds tracked by Wall St. Rank hold HARP as of Q1 2024.
- UBS Group reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- UBS Group sold 2,608 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $29.7K.
- UBS Group first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q2 2019 and held it in 19 quarters.
- UBS Group's Harpoon Therapeutics, Inc. Common Stock position peaked at $199K in Q4 2019.
- 0 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2024.
Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.